(Q33642518)

28 July 2017

1 reference

title

The epidemiology of bacterial sepsis (English)

1 reference

28 July 2017

0 references

1 reference

1 reference

Rangel-Frausto MS

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Infectious Disease Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

13

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

299-312, vii

1 reference

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Pseudomonas aeruginosa Bacteremia: Univariate and Multivariate Analyses of Factors Influencing the Prognosis in 133 Episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Secular trends in nosocomial bloodstream infections in a 55-bed cardiothoracic intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Statistical analysis of the stages of HIV infection using a Markov model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Bacteremia at Boston City Hospital: Occurrence and Mortality during 12 Selected Years (1935-1972), with Special Reference to Hospital-Acquired Cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Bacteremia in a long-term-care facility: a five-year prospective study of 163 consecutive episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

A time-dependent statistical model which relates current clinical status to prognosis: application to advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Septic shock. Hemodynamics and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Predictors of bacteremia and gram-negative bacteremia in patients with sepsis. The Veterans Affairs Systemic Sepsis Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, morbidities and outcomes in surgical ICU patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Long-term survival after intensive care unit admission with sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Major trends in the microbial etiology of nosocomial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Nosocomial bloodstream infections in a newborn intensive care unit: a case-matched control study of morbidity, mortality and risk

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Anti-endotoxin monoclonal antibodies--a second look

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

The mortality of hospital-acquired bloodstream infections: need for a new vital statistic?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Hospital-acquired candidemia. The attributable mortality and excess length of stay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970076-3

7 January 2021

10.1016/S0891-5520(05)70076-3

Identifiers

DOI

1 reference

28 July 2017

1 reference